{"id":"visipaque-270","safety":{"commonSideEffects":[{"rate":null,"effect":"Contrast-induced nephropathy"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Flushing and warmth sensation"},{"rate":null,"effect":"Arrhythmias"}]},"_chembl":{"chemblId":"CHEMBL3663554","moleculeType":"Small molecule","molecularWeight":"508.36"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Visipaque 270 contains iodixanol, an osmotically balanced contrast agent with an osmolality of approximately 290 mOsm/kg, matching that of blood and cerebrospinal fluid. The iodine content (270 mg/mL) attenuates X-rays, allowing enhanced visualization of vascular and organ structures during angiography, coronary angiography, and other radiographic procedures. Its iso-osmolar formulation is designed to minimize osmotic stress on tissues and reduce the risk of contrast-induced nephropathy compared to hyperosmolar agents.","oneSentence":"Visipaque 270 is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and organs during diagnostic imaging procedures.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:16.791Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Coronary angiography and left ventriculography"},{"name":"Peripheral vascular angiography"},{"name":"Cerebral angiography"},{"name":"Renal angiography"},{"name":"Aortography"}]},"trialDetails":[{"nctId":"NCT06176248","phase":"NA","title":"Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis","status":"RECRUITING","sponsor":"CHU de Reims","startDate":"2024-10-11","conditions":"Adhesive Capsulitis","enrollment":62},{"nctId":"NCT03671603","phase":"","title":"Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2018-11-05","conditions":"Coronary Artery Disease, ST-segment Elevation Myocardial Infarction","enrollment":2755},{"nctId":"NCT01843426","phase":"NA","title":"Aortic Stenosis Pre-Transcatheter Aortic Valve Replacement (TAVR) Procedure CT Scan","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2013-02","conditions":"Aortic Valve Stenosis","enrollment":40},{"nctId":"NCT01188486","phase":"NA","title":"Pulmonary Interstitial Lymphography in Early Stage Lung Cancer","status":"TERMINATED","sponsor":"Stanford University","startDate":"2010-08","conditions":"Lung Cancer, Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer Small Cell Lung Cancer (SCLC)","enrollment":12},{"nctId":"NCT01534975","phase":"NA","title":"Comparison of Contrast Agents During CT Angiography","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2012-01","conditions":"Contrast Enhancement on Cardiac CT","enrollment":513},{"nctId":"NCT01146639","phase":"NA","title":"DynaCT in Preoperative Imaging Before Insertion of Stentgraft","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2008-08","conditions":"Abdominal Aortic Aneurysm","enrollment":20},{"nctId":"NCT01075217","phase":"PHASE4","title":"Isovue in Peripheral Digital Subtraction Angiography (DSA)","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2010-04","conditions":"Peripheral Arterial Occlusive Disease","enrollment":174},{"nctId":"NCT00347022","phase":"PHASE4","title":"A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric Indications","status":"COMPLETED","sponsor":"Guerbet","startDate":"2006-05","conditions":"Diagnostic Imaging","enrollment":145},{"nctId":"NCT00740207","phase":"PHASE4","title":"Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral DSA","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2008-09","conditions":"Peripheral Arterial Occlusive Disease","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Iodixanol Injection"],"phase":"marketed","status":"active","brandName":"VISIPAQUE 270","genericName":"VISIPAQUE 270","companyName":"Bracco Diagnostics, Inc","companyId":"bracco-diagnostics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Visipaque 270 is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and organs during diagnostic imaging procedures. Used for Coronary angiography and left ventriculography, Peripheral vascular angiography, Cerebral angiography.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}